210 related articles for article (PubMed ID: 19915448)
21. Resistance mutations in HIV-1 infected pregnant women and their infants receiving antiretrovirals to prevent HIV-1 vertical transmission in China.
Han J; Wang L; Jiang Y; Zhang Q; Fang L; Yao J; Wang Q
Int J STD AIDS; 2009 Apr; 20(4):249-54. PubMed ID: 19304969
[TBL] [Abstract][Full Text] [Related]
22. Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission.
Lehman DA; Chung MH; Mabuka JM; John-Stewart GC; Kiarie J; Kinuthia J; Overbaugh J
J Acquir Immune Defic Syndr; 2009 Aug; 51(5):522-9. PubMed ID: 19502990
[TBL] [Abstract][Full Text] [Related]
23. High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998-2004.
Paredes R; Cheng I; Kuritzkes DR; Tuomala RE
AIDS; 2007 Oct; 21(15):2103-6. PubMed ID: 17885302
[TBL] [Abstract][Full Text] [Related]
24. Response to antiretroviral therapy after a single, peripartum dose of nevirapine.
Lockman S; Shapiro RL; Smeaton LM; Wester C; Thior I; Stevens L; Chand F; Makhema J; Moffat C; Asmelash A; Ndase P; Arimi P; van Widenfelt E; Mazhani L; Novitsky V; Lagakos S; Essex M
N Engl J Med; 2007 Jan; 356(2):135-47. PubMed ID: 17215531
[TBL] [Abstract][Full Text] [Related]
25. Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission.
Hauser A; Sewangi J; Mbezi P; Dugange F; Lau I; Ziske J; Theuring S; Kuecherer C; Harms G; Kunz A
PLoS One; 2012; 7(2):e32055. PubMed ID: 22384138
[TBL] [Abstract][Full Text] [Related]
26. Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi.
Mancinelli S; Galluzzo CM; Andreotti M; Liotta G; Jere H; Sagno JB; Amici R; Pirillo MF; Scarcella P; Marazzi MC; Vella S; Palombi L; Giuliano M
AIDS Res Hum Retroviruses; 2016 Aug; 32(8):737-42. PubMed ID: 27067142
[TBL] [Abstract][Full Text] [Related]
27. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
[TBL] [Abstract][Full Text] [Related]
28. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
[TBL] [Abstract][Full Text] [Related]
29. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
[TBL] [Abstract][Full Text] [Related]
30. Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.
McMahon DK; Zheng L; Hitti J; Chan ES; Halvas EK; Hong F; Kabanda J; Taulo F; Kumarasamy N; Bonhomme J; Wallis CL; Klingman KL; Hughes MD; Mellors JW
Clin Infect Dis; 2013 Apr; 56(7):1044-51. PubMed ID: 23300238
[TBL] [Abstract][Full Text] [Related]
31. HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission.
Samuel R; Julian MN; Paredes R; Parboosing R; Moodley P; Singh L; Naidoo A; Gordon M
J Acquir Immune Defic Syndr; 2016 Dec; 73(4):384-389. PubMed ID: 27327263
[TBL] [Abstract][Full Text] [Related]
32. Rates of HBV, HCV, HDV and HIV type 1 among pregnant women and HIV type 1 drug resistance-associated mutations in breastfeeding women on antiretroviral therapy.
Torimiro JN; Nanfack A; Takang W; Keou CK; Joyce AN; Njefi K; Agyingi K; Domkam I; Takou D; Moudourou S; Sosso S; Mbu RE
BMC Pregnancy Childbirth; 2018 Dec; 18(1):504. PubMed ID: 30577760
[TBL] [Abstract][Full Text] [Related]
33. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.
Moodley D; Moodley J; Coovadia H; Gray G; McIntyre J; Hofmyer J; Nikodem C; Hall D; Gigliotti M; Robinson P; Boshoff L; Sullivan JL;
J Infect Dis; 2003 Mar; 187(5):725-35. PubMed ID: 12599045
[TBL] [Abstract][Full Text] [Related]
34. Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy.
Clarke JR; Braganza R; Mirza A; Stainsby C; Ait-Khaled M; Wright A; Lyall H; Parker D; McClure MO; Weber JN; Taylor GP
J Med Virol; 1999 Nov; 59(3):364-8. PubMed ID: 10502270
[TBL] [Abstract][Full Text] [Related]
35. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
Ndembi N; Goodall RL; Dunn DT; McCormick A; Burke A; Lyagoba F; Munderi P; Katundu P; Kityo C; Robertson V; Yirrell DL; Walker AS; Gibb DM; Gilks CF; Kaleebu P; Pillay D;
J Infect Dis; 2010 Jan; 201(1):106-13. PubMed ID: 19938977
[TBL] [Abstract][Full Text] [Related]
36. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Brocklehurst P; Volmink J
Cochrane Database Syst Rev; 2002; (2):CD003510. PubMed ID: 12076484
[TBL] [Abstract][Full Text] [Related]
37. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Brocklehurst P; Volmink J
Cochrane Database Syst Rev; 2002; (1):CD003510. PubMed ID: 11869666
[TBL] [Abstract][Full Text] [Related]
38. Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention.
Muro EP; Fillekes Q; Kisanga ER; L'homme R; Aitken SC; Mariki G; Van der Ven AJ; Dolmans W; Schuurman R; Walker AS; Gibb DM; Burger DM
J Acquir Immune Defic Syndr; 2012 Mar; 59(3):266-73. PubMed ID: 22134145
[TBL] [Abstract][Full Text] [Related]
39. Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.
Chung MH; Kiarie JN; Richardson BA; Lehman DA; Overbaugh J; Kinuthia J; Njiri F; John-Stewart GC
Antivir Ther; 2008; 13(6):799-807. PubMed ID: 18839781
[TBL] [Abstract][Full Text] [Related]
40. Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
Kurle SN; Gangakhedkar RR; Sen S; Hayatnagarkar SS; Tripathy SP; Paranjape RS
AIDS Res Hum Retroviruses; 2007 May; 23(5):682-5. PubMed ID: 17530993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
